MPTP: Insights into the Etiology of Parkinson’s Disease
- 1 January 1987
- journal article
- research article
- Published by S. Karger AG in European Neurology
- Vol. 26 (1), 2-10
- https://doi.org/10.1159/000116349
Abstract
MPTP-induced parkinsonism in humans faithfully replicates the clinical features of Parkinson''s disease, including physical findings, response to therapy and even complications of therapy. Further, the neuropathological picture in experimental animals appears to be drawing much closer to that seen in the idiopathic disease, particularly in the light of recent findings showing involvement of the locus ceruleus as well as the substantia nigra, and the presence of eosinophilic inclusion bodies. It is suggested that them ore closely the MPTP model comes to reproducing Parkinson''s disease, the more valuable it may be in exploring the etiology of the disease. MPTP could provide insights into mechanisms underlying neuronal degeneration in the substantia nigra and other areas of the brain in Parkinson''s disease, and has already set in motion a renewed search for possible environmental causes of the disease.This publication has 8 references indexed in Scilit:
- A parkinson-like neurologic deficit in primates is caused by a novel 4-substituted piperidineBrain Research, 1986
- 1-Methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine (2′-CH3-MPTP) is a more potent dopaminergic neurotoxin than MPTP in miceEuropean Journal of Pharmacology, 1986
- Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)Neurology, 1985
- Chronic low‐dose levodopa therapy in Parkinson's diseaseNeurology, 1984
- Parkinson's disease in 65 pairs of twins and in a set of quadrupletsNeurology, 1983
- Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog SynthesisScience, 1983
- Cigarette smoking and Parkinson diseaseNeurology, 1980
- OXIDATIVE PATHWAYS FOR CATECHOLAMINES IN GENESIS OF NEUROMELANIN AND CYTOTOXIC QUINONES1978